Abeona Therapeutics (NASDAQ:ABEO) Releases Earnings Results, Misses Expectations By $0.12 EPS

Abeona Therapeutics (NASDAQ:ABEO) released its earnings results on Thursday. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.12), FiscalAI reports. The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million, with four revenue-generating treatments recognized in the second quarter. Abeona ended June with $146.8 million in cash, cash equivalents, and short-term investments.
• The commercial rollout expanded to seven activated qualified treatment centers, and 12 patients have been treated since launch, including five in Q2 and three more in Q3 to date. The company estimates about 40% of its addressable market now has in-state access to a treatment center.
• Launch execution remains operationally complex, with scheduling disruptions, two last-minute biopsy cancellations, one low-yield batch, and one out-of-specification batch. Both affected patients were treated, but Abeona will recognize no revenue for those two treatments and said the long-term rate of non-billable units remains uncertain.
• CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, making it one of only three of 15 traditional-pathway applicants to receive the designation. Although Medicare represents roughly 10% of the payer mix, Abeona expects NTAP to improve hospital economics and potentially support broader payer negotiations.
• Abeona reported a second-quarter net loss of $20.2 million, or $0.35 per share, compared with a $17.1 million loss in Q1. Gross margin was approximately 63%, though management expects margins could reach 85%–90% at steady-state volume as fixed manufacturing costs are spread across more treatments.

Abeona Therapeutics Price Performance

Shares of ABEO stock traded down $1.11 on Thursday, hitting $6.34. 4,547,331 shares of the company’s stock were exchanged, compared to its average volume of 1,240,964. The company has a 50 day moving average of $6.29 and a 200 day moving average of $5.56. The stock has a market cap of $361.60 million, a P/E ratio of 6.54 and a beta of 1.35. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.89 and a quick ratio of 5.70. Abeona Therapeutics has a 12 month low of $4.00 and a 12 month high of $7.65.

Insider Transactions at Abeona Therapeutics

In other news, CEO Vishwas Seshadri sold 67,971 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $6.96, for a total value of $473,078.16. Following the sale, the chief executive officer directly owned 1,306,108 shares in the company, valued at approximately $9,090,511.68. This trade represents a 4.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Madhav Vasanthavada sold 12,606 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $6.96, for a total transaction of $87,737.76. Following the completion of the sale, the insider owned 290,623 shares in the company, valued at approximately $2,022,736.08. The trade was a 4.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 307,221 shares of company stock valued at $1,854,494. Company insiders own 7.10% of the company’s stock.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new position in shares of Abeona Therapeutics during the third quarter worth $37,000. Truvestments Capital LLC increased its holdings in shares of Abeona Therapeutics by 191.4% during the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 6,770 shares in the last quarter. Man Group plc bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at $67,000. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $64,000. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Weiss Ratings cut shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, August 3rd. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, May 28th. Finally, Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Abeona Therapeutics presently has an average rating of “Hold” and a consensus price target of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.